273 related articles for article (PubMed ID: 20587661)
1. Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer.
Schwartz DL; Bankson JA; Lemos R; Lai SY; Thittai AK; He Y; Hostetter G; Demeure MJ; Von Hoff DD; Powis G
Mol Cancer Ther; 2010 Jul; 9(7):2057-67. PubMed ID: 20587661
[TBL] [Abstract][Full Text] [Related]
2. The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects.
Schwartz DL; Powis G; Thitai-Kumar A; He Y; Bankson J; Williams R; Lemos R; Oh J; Volgin A; Soghomonyan S; Nishii R; Alauddin M; Mukhopadhay U; Peng Z; Bornmann W; Gelovani J
Mol Cancer Ther; 2009 Apr; 8(4):947-58. PubMed ID: 19372568
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma.
Zhao T; Ren H; Jia L; Chen J; Xin W; Yan F; Li J; Wang X; Gao S; Qian D; Huang C; Hao J
Oncotarget; 2015 Feb; 6(4):2250-62. PubMed ID: 25544770
[TBL] [Abstract][Full Text] [Related]
4. PX-478, an inhibitor of hypoxia-inducible factor-1alpha, enhances radiosensitivity of prostate carcinoma cells.
Palayoor ST; Mitchell JB; Cerna D; Degraff W; John-Aryankalayil M; Coleman CN
Int J Cancer; 2008 Nov; 123(10):2430-7. PubMed ID: 18729192
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha.
Welsh S; Williams R; Kirkpatrick L; Paine-Murrieta G; Powis G
Mol Cancer Ther; 2004 Mar; 3(3):233-44. PubMed ID: 15026543
[TBL] [Abstract][Full Text] [Related]
6. Arsenic trioxide plus PX-478 achieves effective treatment in pancreatic ductal adenocarcinoma.
Lang M; Wang X; Wang H; Dong J; Lan C; Hao J; Huang C; Li X; Yu M; Yang Y; Yang S; Ren H
Cancer Lett; 2016 Aug; 378(2):87-96. PubMed ID: 27212442
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha.
Koh MY; Spivak-Kroizman T; Venturini S; Welsh S; Williams RR; Kirkpatrick DL; Powis G
Mol Cancer Ther; 2008 Jan; 7(1):90-100. PubMed ID: 18202012
[TBL] [Abstract][Full Text] [Related]
8. A novel approach to cancer therapy using PX-478 as a HIF-1α inhibitor.
Lee K; Kim HM
Arch Pharm Res; 2011 Oct; 34(10):1583-5. PubMed ID: 22076756
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia triggers hedgehog-mediated tumor-stromal interactions in pancreatic cancer.
Spivak-Kroizman TR; Hostetter G; Posner R; Aziz M; Hu C; Demeure MJ; Von Hoff D; Hingorani SR; Palculict TB; Izzo J; Kiriakova GM; Abdelmelek M; Bartholomeusz G; James BP; Powis G
Cancer Res; 2013 Jun; 73(11):3235-47. PubMed ID: 23633488
[TBL] [Abstract][Full Text] [Related]
10. Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice.
Jacoby JJ; Erez B; Korshunova MV; Williams RR; Furutani K; Takahashi O; Kirkpatrick L; Lippman SM; Powis G; O'Reilly MS; Herbst RS
J Thorac Oncol; 2010 Jul; 5(7):940-9. PubMed ID: 20512076
[TBL] [Abstract][Full Text] [Related]
11. Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478.
Jordan BF; Runquist M; Raghunand N; Baker A; Williams R; Kirkpatrick L; Powis G; Gillies RJ
Neoplasia; 2005 May; 7(5):475-85. PubMed ID: 15967100
[TBL] [Abstract][Full Text] [Related]
12. Effect of small interference RNA targeting HIF-1alpha mediated by rAAV combined L: -ascorbate on pancreatic tumors in athymic mice.
Chen C; Sun J; Liu G; Chen J
Pathol Oncol Res; 2009 Mar; 15(1):109-14. PubMed ID: 18509748
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of HSP90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer.
Nagaraju GP; Zakka KM; Landry JC; Shaib WL; Lesinski GB; El-Rayes BF
Int J Cancer; 2019 Sep; 145(6):1529-1537. PubMed ID: 30801702
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia-inducible factor-1 up-regulates the expression of Toll-like receptor 4 in pancreatic cancer cells under hypoxic conditions.
Fan P; Zhang JJ; Wang B; Wu HQ; Zhou SX; Wang CY; Zhang JH; Tian Y; Wu HS
Pancreatology; 2012; 12(2):170-8. PubMed ID: 22487528
[TBL] [Abstract][Full Text] [Related]
15. Identification of thioredoxin-interacting protein 1 as a hypoxia-inducible factor 1alpha-induced gene in pancreatic cancer.
Baker AF; Koh MY; Williams RR; James B; Wang H; Tate WR; Gallegos A; Von Hoff DD; Han H; Powis G
Pancreas; 2008 Mar; 36(2):178-86. PubMed ID: 18376310
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia-inducible factor-1α expression and gemcitabine chemotherapy for pancreatic cancer.
Kasuya K; Tsuchida A; Nagakawa Y; Suzuki M; Abe Y; Itoi T; Serizawa H; Nagao T; Shimazu M; Aoki T
Oncol Rep; 2011 Dec; 26(6):1399-406. PubMed ID: 21922147
[TBL] [Abstract][Full Text] [Related]
17. Effects of the silencing of hypoxia-inducible Factor-1 alpha on metastasis of pancreatic cancer.
Wei H; Li F; Fu P; Liu X
Eur Rev Med Pharmacol Sci; 2013 Feb; 17(4):436-46. PubMed ID: 23467940
[TBL] [Abstract][Full Text] [Related]
18. Metabolite changes in HT-29 xenograft tumors following HIF-1alpha inhibition with PX-478 as studied by MR spectroscopy in vivo and ex vivo.
Jordan BF; Black K; Robey IF; Runquist M; Powis G; Gillies RJ
NMR Biomed; 2005 Nov; 18(7):430-9. PubMed ID: 16206237
[TBL] [Abstract][Full Text] [Related]
19. Metabolic targeting of HIF-dependent glycolysis reduces lactate, increases oxygen consumption and enhances response to high-dose single-fraction radiotherapy in hypoxic solid tumors.
Leung E; Cairns RA; Chaudary N; Vellanki RN; Kalliomaki T; Moriyama EH; Mujcic H; Wilson BC; Wouters BG; Hill R; Milosevic M
BMC Cancer; 2017 Jun; 17(1):418. PubMed ID: 28619042
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of HIF-1α enhances anti-tumor effects of dendritic cell-based vaccination in a mouse model of breast cancer.
Kheshtchin N; Arab S; Ajami M; Mirzaei R; Ashourpour M; Mousavi N; Khosravianfar N; Jadidi-Niaragh F; Namdar A; Noorbakhsh F; Hadjati J
Cancer Immunol Immunother; 2016 Oct; 65(10):1159-67. PubMed ID: 27497816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
